At the news
? BEARISHIMPACT 8/10 8-K filed May 13, 2026 at 08:03 ET
Reviva Pharmaceuticals received a final delisting notice from Nasdaq due to failure to maintain the minimum $1.00 bid price. Trading will be suspended on May 14, 2026, and the stock will transition to the OTCQB Venture Market. The delisting severely reduces liquidity and institutional access, compounding distress signaled by recent dilutive offerings.
- Nasdaq Hearings Panel determined to delist common stock due to non-compliance with Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)).
- Trading on Nasdaq will be suspended as of open of trading on May 14, 2026.
- Common stock will be quoted on OTCQB Venture Market under symbol RVPH starting May 14, 2026.
- Company filed two 424B5 offerings in March 2026 (approximately 55-56 days prior), indicating recent capital raises that failed to regain compliance.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access